アバスチンの薬剤に関する洞察と市場予測：2032年

アバスチン（ベバシズマブ）は遺伝子組換えヒト化モノクローナルIgG1抗体であり、標的である血管内皮増殖因子（VEGF）を阻害することにより血管新生阻害剤として作用します。ベバシズマブは、内皮細胞表面に存在するVEGFの受容体VEGFR-1およびVEGFR-2と結合します。これにより、VEGFの活性を低下させ、腫瘍の脈管形成を退縮させ、腫瘍脈管系を正常化し、新たな腫瘍脈管系の形成を抑制することで、腫瘍の増殖を防ぐことができます。VEGFは様々な疾患、特にがんにおいて血管新生を刺激する化学シグナルです。ベバシズマブは米国で初めて臨床使用可能な血管新生阻害薬です。

今後数年間で、多形性膠芽腫（GBM）の市場シナリオは、世界中の広範な研究と医療支出の増加により変化します。各社は、病状を治療／改善するための新たなアプローチに焦点を当てた治療法を開発し、課題を評価し、アバスチンの優位性に影響を与える可能性のある機会を模索しています。GBMに対する他の新興製品がアバスチンに厳しい市場競争をもたらすと予想され、近い将来、後発の新興治療薬が発売されれば、市場に大きな影響を与えるとみられています。

当レポートでは、主要7ヶ国におけるアバスチン市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 多形性膠芽腫（GBM）に対するアバスチンの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品概要

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 アバスチン市場評価

• GBMに対するアバスチンの市場見通し
• 主要7ヶ国市場分析
  • 主要7ヶ国におけるGBMに対するアバスチンの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: AVASTIN, Clinical Trial Description, 2023
• Table 2: AVASTIN, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: AVASTIN Market Size in the 7MM, in USD million (2019-2032)
• Table 6: AVASTIN Market Size in the US, in USD million (2019-2032)
• Table 7: AVASTIN Market Size in Germany, in USD million (2019-2032)
• Table 8: AVASTIN Market Size in France, in USD million (2019-2032)
• Table 9: AVASTIN Market Size in Italy, in USD million (2019-2032)
• Table 10: AVASTIN Market Size in Spain, in USD million (2019-2032)
• Table 11: AVASTIN Market Size in the UK, in USD million (2019-2032)
• Table 12: AVASTIN Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: AVASTIN Market Size in the 7MM, USD million (2019-2032)
• Figure 2: AVASTIN Market Size in the United States, USD million (2019-2032)
• Figure 3: AVASTIN Market Size in Germany, USD million (2019-2032)
• Figure 4: AVASTIN Market Size in France, USD million (2019-2032)
• Figure 5: AVASTIN Market Size in Italy, USD million (2019-2032)
• Figure 6: AVASTIN Market Size in Spain, USD million (2019-2032)
• Figure 7: AVASTIN Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: AVASTIN Market Size in Japan, USD million (2019-2032)

“"AVASTIN Drug Insight and Market Forecast - 2032" report provides comprehensive insights about AVASTIN for glioblastoma multiforme (GBM) in the seven major markets. A detailed picture of the AVASTIN for GBM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the AVASTIN for GBM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AVASTIN market forecast analysis for GBM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in GBM.

Drug Summary:

AVASTIN (bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as an angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the VEGF with its receptors VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. This helps reduce VEGF activity and regress the vascularization of tumors, normalizing the tumor vasculature and inhibiting the formation of new tumor vasculature, thereby preventing tumor growth. VEGF is a chemical signal that stimulates angiogenesis in various diseases, especially cancer. Bevacizumab is the first clinically available angiogenesis inhibitor in the United States. In September 2014, Genentech reclassified the drug under "Specialty drugs," only to be available through specialty pharmacies (under FDA's risk evaluation and mitigation strategy [REMS] program) (Genentech, n.d.). AVASTIN is indicated for treating GBM with progressive disease in adult patients following prior therapy as a single agent. The effectiveness of AVASTIN in GBM is based on an improvement in objective response rate. No available data demonstrate any improvement in disease-related symptoms or increased survival with AVASTIN in GBM.

Dosage: 10 mg/kg IV every 2 weeks.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AVASTIN description, mechanism of action, dosage and administration, research and development activities in glioblastoma multiforme (GBM).
• Elaborated details on AVASTIN regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AVASTIN research and development activities in GBM across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around AVASTIN.
• The report contains forecasted sales of AVASTIN for GBM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for GBM.
• The report also features the SWOT analysis with analyst views for AVASTIN in GBM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AVASTIN Analytical Perspective by DelveInsight

In-depth AVASTIN Market Assessment

This report provides a detailed market assessment of AVASTIN for glioblastoma multiforme (GBM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

AVASTIN Clinical Assessment

The report provides the clinical trials information of AVASTIN for GBM covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for glioblastoma multiforme (GBM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AVASTIN dominance.
• Other emerging products for GBM are expected to give tough market competition to AVASTIN and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AVASTIN in GBM.
• Our in-depth analysis of the forecasted sales data of AVASTIN from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AVASTIN in GBM.

Key Questions:

• What is the product type, route of administration and mechanism of action of AVASTIN?
• What is the clinical trial status of the study related to AVASTIN in glioblastoma multiforme (GBM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AVASTIN development?
• What are the key designations that have been granted to AVASTIN for GBM?
• What is the forecasted market scenario of AVASTIN for GBM?
• What are the forecasted sales of AVASTIN in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to AVASTIN for GBM?
• Which are the late-stage emerging therapies under development for the treatment of GBM?

Table of Contents

1. Report Introduction

2. AVASTIN Overview in GBM

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. AVASTIN Market Assessment

• 5.1. Market Outlook of AVASTIN in GBM
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of AVASTIN in the 7MM for GBM
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of AVASTIN in the United States for GBM
  • 5.3.2. Market Size of AVASTIN in Germany for GBM
  • 5.3.3. Market Size of AVASTIN in France for GBM
  • 5.3.4. Market Size of AVASTIN in Italy for GBM
  • 5.3.5. Market Size of AVASTIN in Spain for GBM
  • 5.3.6. Market Size of AVASTIN in the United Kingdom for GBM
  • 5.3.7. Market Size of AVASTIN in Japan for GBM

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options